PolyPid Ltd. (PYPD)
Automate Your Wheel Strategy on PYPD
With Tiblio's Option Bot, you can configure your own wheel strategy including PYPD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PYPD
- Rev/Share 0.0
- Book/Share 1.4338
- PB 2.5666
- Debt/Equity 1.2516
- CurrentRatio 1.3069
- ROIC -1.3865
- MktCap 37502512.0
- FreeCF/Share 0.0
- PFCF 0.0
- PE -0.6795
- Debt/Assets 0.3813
- DivYield 0
- ROE -6.2453
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PYPD | Roth Capital | -- | Buy | -- | $9 | June 5, 2025 |
| Resumed | PYPD | H.C. Wainwright | -- | Buy | -- | $11 | June 2, 2025 |
| Initiation | PYPD | Rodman & Renshaw | -- | Buy | -- | $13 | Jan. 28, 2025 |
News
PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future
Read More
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology
Read More
PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
PolyPid Ltd. (NASDAQ:PYPD ) Q1 2025 Earnings Call May 14, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer, U.S. Conference Call Participants Roy Buchanan - JMP Securities Chase Knickerbocker - Craig-Hallum Bupalan Pachaiyappan - ROTH Capital Brian Ritchie Thank you all for participating in PolyPid's First Quarter 2025 Earnings Conference Call.
Read More
PolyPid to Participate in The Citizens Life Sciences Conference
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025.
Read More
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enroll ed more than 7 00 P atients to D ate; Enrollment Completion Expected in March 202 5 , with T op- L ine Results Anticipated in Second Quarter of 2025 Company Completed Private Placement of Up to $41 Million; Proceeds and Exercise of Data-Triggered Warrant s Expected to Extend Cash Runway Beyond Potential NDA Approval Conference Call S cheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” …
Read More
About PolyPid Ltd. (PYPD)
- IPO Date 2020-06-26
- Website https://www.polypid.com
- Industry Biotechnology
- CEO Ms. Dikla Czaczkes Akselbrad
- Employees 57